LUPIN LTP 2,113
| Counter | LUPIN LTP 2,113 |
| Call | Buy-On-Dip |
| Target 1 | 2,245 |
| Target 2 | 2,300 |
| Stop Loss | 1,982 (Closing Basis) |
| Time Horizon | 2-3 months |
Lupin Limited is a transnational pharmaceutical company engaged in the manufacture of generic and branded formulations as well as bulk drugs. The company produces Active Pharmaceutical Ingredients (APIs) and a wide range of formulations across key therapeutic segments such as cephalosporins, CVS, CNS, anti-asthma, anti-TB, diabetology, dermatology, GI, and others. Its API portfolio includes products like Cephalexin, Cefaclor, Rifaximin, Rifampicin, Lisinopril, Simvastatin, Prasugrel, Levetiracetam, Pregabalin, and Febuxostat, among others. As of March 31, 2012, Lupin Limited had 19 subsidiaries.
| Previous Close | 2,081.80 | TTM EPS | 94.68 |
| 52 Week High | 2,402.90 | TTM PE | 22.32 |
| 52 Week Low | 1,795.20 | P/B | 5.62 |
| Sector PE | 39.92 | Mkt Cap (Rs. Cr.) | 96,563 |
(Source: Moneycontrol, BSE, Fisdom Research)
Technical Outlook
(Source: Fisdom research)- LUPIN on the weekly chart has given a triangle pattern breakout, and prices have closed above the resistance trend line of the pattern.
- The stock on the daily chart is trading in a higher high, higher low formation.
- A higher-than-average volume would confirm the breakout’s strength and suggest that the upward move has solid backing.
- The prices are trading above their 21 and 50 EMA, acting as a cushion support for the stock. The RSI has witnessed a rectangle pattern breakout near the 60 level, on the weekly chart, reinforcing the bullish outlook and signalling sustained positive momentum.
